Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Deepika MalikMohamed TarekJavier Caceres del CarpioClaudio RamirezDavid BoyerM Cristina KenneyBaruch D Kuppermann

Published in: The British journal of ophthalmology (2014)

At clinical doses, neither ranibizumab nor aflibercept produced evidence of mitochondrial toxicity or cell death. However, bevacizumab and ziv-aflibercept showed mild mitochondrial toxicity at clinically relevant doses.

Keyphrases

age related macular degeneration
oxidative stress
cell death
endothelial cells
induced apoptosis
cell cycle arrest
diabetic retinopathy
vascular endothelial growth factor
signaling pathway
drug induced